GSK loses out to Pfizer in supplying UK market with RSV vaccine

[cafead]

via GSK lost out to a key rival in the battle to supply respiratory syncytial virus (RSV) vaccines for the UK’s upcoming immunisation programme, dealing a blow to the drugmaker on its home turf. In documents published Monday, the UK Health Security Agency said that Pfizer’s RSV shot Abrysvo has been chosen ahead of GSK’s Arexvy.

article source